FOR OFFICIAL USE ONLY

ACCESS DB # 190634
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 5-19-2006
Art Unit: 1654 Phone Number: 2-0969 Serial Number: 10/674,516 2003
Location (Bldg/Room#): REM 3D19 (Mailbox #): REM 3C18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Novel Peptide With Osteogenic Activity

Inventors (please provide full names): S. Dhanaraj, A. Gosiewska, A. Rezania, G. Heavner, X. Lin, C. Yi

Earliest Priority Date: 9-10-2004

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the following partial structure:



where R is $-CH_2-SH$, $-CH_2-CH_2-SH$, or $-C(CH_3)_2-SH$.

Please require any hits to have publication dates of 2005 or 2006 (this is an update search).

Thank you.

****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: 6/1/06
Date Completed: 6/5/06
Searcher Prep & Review Time: 30
Online Time: 12

Type of Search
___ NA Sequence (#)
___ AA Sequence (#)
___ Structure (#)
___ Bibliographic
___ Litigation
___ Fulltext
___ Other

Vendors and cost where applicable
✓ STN ___ Dialog
___ Questel/Orbit ___ Lexis/Nexis
___ Westlaw ___ WWW/Internet
___ In-house sequence systems
___ Commercial ___ Oligomer ___ Score/Length
___ Interference ___ SPDI ___ Encode/Transl
___ Other (specify)

```
=> file reg
FILE 'REGISTRY' ENTERED AT 12:56:28 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 JUN 2006  HIGHEST RN 886746-35-6
DICTIONARY FILE UPDATES:   4 JUN 2006  HIGHEST RN 886746-35-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\russel 516.str
```



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 27 37 38 39 40 41 42 43 44 45 46
ring nodes :
28 29 30 31 32 33 34 35 36
chain bonds :
1-2 2-3 2-15 3-4 4-5 4-20 5-6 5-16 6-7 7-8 7-27 8-9 8-17 9-10 10-11
10-37 11-12 11-18 12-13 13-14 14-19 20-21 21-22 22-23 22-24 27-29 38-39
40-41 41-42
43-44 43-45 43-46
ring bonds :
28-33 28-29 28-32 29-30 30-31 31-32 32-36 33-34 34-35 35-36
exact/norm bonds :
1-2 2-3 2-15 3-4 4-5 5-6 5-16 6-7 7-8 7-27 8-9 8-17 9-10 10-11 10-37
11-12 11-18 12-13 13-14 14-19 21-22 22-23 22-24 28-33 28-29 28-32 29-30
30-31 31-32
32-36 33-34 34-35 35-36 43-46
exact bonds :
4-20 20-21 27-29 38-39 40-41 41-42 43-44 43-45

G1:[*1],[*2],[*3]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:Atom 29:Atom
30:Atom 31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS 42:CLASS
43:CLASS 44:CLASS 45:CLASS 46:CLASS

L1 STRUCTURE UPLOADED

=> d que
L1 STR



G1 [@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

```
=> d his nofile

     (FILE 'HOME' ENTERED AT 12:56:24 ON 05 JUN 2006)

     FILE 'REGISTRY' ENTERED AT 12:56:28 ON 05 JUN 2006
L1              STRUCTURE UPLOADED
                D QUE
L2            1 SEA SSS SAM L1
                D SCAN
L3            9 SEA SSS FUL L1

     FILE 'CAPLUS' ENTERED AT 13:00:24 ON 05 JUN 2006
L4           13 SEA ABB=ON  PLU=ON  L3
L5           11 SEA ABB=ON  PLU=ON  L4 AND (PY>=2005 OR AY>=2005 AND PRY>=2005)

                D BIB

     FILE 'REGISTRY' ENTERED AT 13:01:50 ON 05 JUN 2006

     FILE 'CAPLUS' ENTERED AT 13:02:19 ON 05 JUN 2006
                E DHANARAJ S/AU
L6           38 SEA ABB=ON  PLU=ON  ("DHANARAJ S"/AU OR "DHANARAJ S A"/AU OR
                "DHANARAJ SRIDEVI"/AU OR "DHANARAJ SRIDEVI N"/AU OR "DHANARAJ
                SRIDEVI NAIDU"/AU)
                E GOSIEWSKA A/AU
L7           38 SEA ABB=ON  PLU=ON  ("GOSIEWSKA A"/AU OR "GOSIEWSKA ANNA"/AU)
                E REZANIA A/AU
L8            3 SEA ABB=ON  PLU=ON  ("REZANIA A"/AU OR "REZANIA ALI"/AU)
                E HEAVNER G/AU
L9          116 SEA ABB=ON  PLU=ON  ("HEAVNER G A"/AU OR "HEAVNER GEORGE"/AU
                OR "HEAVNER GEORGE A"/AU)
                E LIN X/AU
L10        4305 SEA ABB=ON  PLU=ON  LIN X?/AU
L11         613 SEA ABB=ON  PLU=ON  YI C?/AU
L12          15 SEA ABB=ON  PLU=ON  (L6 AND (L7 OR L8 OR L9 OR L10 OR L11)) OR
                (L7 AND (L8 OR L9 OR L10 OR L11)) OR (L8 AND (L9 OR L10 OR
                L11)) OR (L9 AND (L10 OR L11)) OR (L10 AND L11)

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:07:17 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Jun 2006  VOL 144 ISS 24
FILE LAST UPDATED: 4 Jun 2006  (20060604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
```

They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> d que l12
L6            38 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("DHANARAJ S"/AU OR "DHANARAJ
                 S A"/AU OR "DHANARAJ SRIDEVI"/AU OR "DHANARAJ SRIDEVI N"/AU OR
                 "DHANARAJ SRIDEVI NAIDU"/AU)
L7            38 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("GOSIEWSKA A"/AU OR "GOSIEWSKA
                  ANNA"/AU)
L8             3 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("REZANIA A"/AU OR "REZANIA
                 ALI"/AU)
L9           116 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("HEAVNER G A"/AU OR "HEAVNER
                 GEORGE"/AU OR "HEAVNER GEORGE A"/AU)
L10         4305 SEA FILE=CAPLUS ABB=ON  PLU=ON  LIN X?/AU
L11          613 SEA FILE=CAPLUS ABB=ON  PLU=ON  YI C?/AU
L12           15 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L6 AND (L7 OR L8 OR L9 OR L10
                 OR L11)) OR (L7 AND (L8 OR L9 OR L10 OR L11)) OR (L8 AND (L9
                 OR L10 OR L11)) OR (L9 AND (L10 OR L11)) OR (L10 AND L11)


=> d ibib abs l12 tot

L12  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:323999  CAPLUS
DOCUMENT NUMBER:          142:386021
TITLE:                    Peptide with osteogenic activity, and therapeutic use
INVENTOR(S):              Dhanaraj, Sridevi; Gosiewska, Anna
                          ; Rezania, Ali; Heavner, George A.
                          ; Lin, Xuanhan; Yi, Chin-Feng
PATENT ASSIGNEE(S):       Ethicon, Inc., USA
SOURCE:                   PCT Int. Appl., 47 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.          DATE
     --------------      ----   --------   --------------------     --------
     WO 2005032461        A2    20050414   WO 2004-US29649          20040910
     WO 2005032461        A3    20050707
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 2005187162        A1    20050825   US 2003-674516           20030930
PRIORITY APPLN. INFO.:                     US 2003-674516      A    20030930
OTHER SOURCE(S):          MARPAT 142:386021
AB   The invention provides a composition including an isolated or recombinant
     peptide component that has osteogenic cell proliferative activity.  The
```

peptide, which promotes proliferation of osteoblasts, is useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis and periodontic diseases, and for prevention of fractures associated with osteoporosis and rheumatoid arthritis. The peptide, or cells that have been genetically engineered to produce the peptide, can be combined with a bone-compatible matrix to facilitate slow release of the peptide to a treatment site and/or provide a structure for developing bone.

L12 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:34885 CAPLUS
DOCUMENT NUMBER: 142:130333
TITLE: Isolation, culture, characterization and therapeutic use of postpartum cells derived from human umbilical cord
INVENTOR(S): Mistry, Sanjay; Kihm, Anthony J.; Harris, Ian Ross; Harmon, Alexander M.; Messina, Darin J.; Seyda, Agnieszka; **Yi, Chin-Feng; Gosiewska, Anna**
PATENT ASSIGNEE(S): Ethicon, Incorporated, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003334	A2	20050113	WO 2004-US20931	20040625
WO 2005003334	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004254616	A1	20050113	AU 2004-254616	20040625
CA 2530533	AA	20050113	CA 2004-2530533	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625
US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1641913 A2 20060405 EP 2004-756395 20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
EP 1649013 A2 20060426 EP 2004-809466 20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-483264P P 20030627
WO 2004-US20931 W 20040625
WO 2004-US20958 W 20040625

AB Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use (such as transplantation). Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

L12 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:12044 CAPLUS
TITLE: Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
INVENTOR(S): Harris, Ian Ross; Harmon, Alexander M.; Kihm, Anthony J.; Messina, Darin J.; Mistry, Sanjay; Seyda, Agnieszka; **Yi, Chin-feng**; **Gosiewska, Anna**
PATENT ASSIGNEE(S): Ethicon, Incorporated, USA
SOURCE: PCT Int. Appl.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM: COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001080	A2	20050106	WO 2004-US20957	20040625
WO 2005001080	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004252571	A1	20050106	AU 2004-252571	20040625
CA 2530422	AA	20050106	CA 2004-2530422	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625

US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1641918	A2	20060405	EP 2004-777287	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

EP 1649013	A2	20060426	EP 2004-809466	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:

US 2003-483264P	P	20030627
WO 2004-US20957	W	20040625
WO 2004-US20958	W	20040625

AB Cells derived from postpartum tissue are disclosed along with methods for their therapeutic use in diseases of the heart or circulatory system are disclosed. Cells may be used therapeutically in either differentiated or undifferentiated forms, in homogenous cultures, or as populations with other cells, and in conjunction with other bioactive factors.

L12 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:12043 CAPLUS

TITLE: Soft tissue repair and regeneration using postpartum-derived cells

INVENTOR(S): Harmon, Alexander M.; Harris, Ian Ross; Kihm, Anthony J.; Mistry, Sanjay; Messina, Darin J.; Seyda, Agnieszka; **Yi, Chin-feng**; **Gosiewska, Anna**

PATENT ASSIGNEE(S): Ethicon, Incorporated, USA

SOURCE: PCT Int. Appl.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001079	A2	20050106	WO 2004-US20956	20040625
WO 2005001079	A3	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004252570	A1	20050106	AU 2004-252570	20040625
CA 2530255	AA	20050106	CA 2004-2530255	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625
US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1641917	A2	20060405	EP 2004-777286	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

EP 1649013	A2	20060426	EP 2004-809466	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:	US 2003-483264P	P	20030627
	WO 2004-US20956	W	20040625
	WO 2004-US20958	W	20040625

AB Cells derived from postpartum tissue having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.

L12 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2005:12042 CAPLUS
TITLE:	Regeneration and repair of neural tissue using postpartum-derived cells
INVENTOR(S):	Messina, Darin J.; Mistry, Sanjay; Harmon, Alexander M.; Harris, Ian Ross; Kihm, Anthony J.; Seyda, Agnieszka; **Yi, Chin-feng**; **Gosiewska, Anna**
PATENT ASSIGNEE(S):	Ethicon, Incorporated, USA
SOURCE:	PCT Int. Appl. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001078	A2	20050106	WO 2004-US20823	20040625
WO 2005001078	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004252568	A1	20050106	AU 2004-252568	20040625
CA 2530732	AA	20050106	CA 2004-2530732	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625
US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641916	A2	20060405	EP 2004-777235	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
EP 1649013	A2	20060426	EP 2004-809466	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:	US 2003-483264P	P	20030627
	WO 2004-US20823	W	20040625
	WO 2004-US20958	W	20040625

AB Cells derived from postpartum umbilicus and placenta re disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.

L12 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:12041 CAPLUS
TITLE: Repair and regeneration of ocular tissue using postpartum-derived cells

INVENTOR(S): Mistry, Sanjay; Messina, Darin J.; Harris, Ian Ross; Harmon, Alexander M.; Kihm, Anthony J.; Seyda, Agnieszka; **Yi, Chin-feng; Gosiewska, Anna**
PATENT ASSIGNEE(S): Ethicon, Incorporated, USA
SOURCE: PCT Int. Appl.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001077	A2	20050106	WO 2004-US20822	20040625
WO 2005001077	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004252567	A1	20050106	AU 2004-252567	20040625
CA 2530421	AA	20050106	CA 2004-2530421	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625
US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641915	A2	20060405	EP 2004-777234	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
EP 1649013	A2	20060426	EP 2004-809466	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-483264P P 20030627
WO 2004-US20822 W 20040625

WO 2004-US20958 W 20040625

AB Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

L12 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:12040 CAPLUS
TITLE: Postpartum cells derived from placental tissue, and methods of making and using the same
INVENTOR(S): Kihm, Anthony J.; Harris, Ian Ross; Mistry, Sanjay; Harmon, Alexander M.; Messina, Darin J.; Seyda, Agnieszka; **Yi, Chin-feng; Gosiewska, Anna**
PATENT ASSIGNEE(S): Ethicon, Incorporated, USA
SOURCE: PCT Int. Appl.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001076	A2	20050106	WO 2004-US20816	20040625
WO 2005001076	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004252566	A1	20050106	AU 2004-252566	20040625
CA 2530416	AA	20050106	CA 2004-2530416	20040625
US 2005019865	A1	20050127	US 2004-876998	20040625
US 2005032209	A1	20050210	US 2004-877269	20040625
US 2005037491	A1	20050217	US 2004-877541	20040625
US 2005054098	A1	20050310	US 2004-877012	20040625
US 2005058629	A1	20050317	US 2004-877009	20040625
US 2005058630	A1	20050317	US 2004-877445	20040625
US 2005058631	A1	20050317	US 2004-877446	20040625
AU 2004281371	A1	20050428	AU 2004-281371	20040625
CA 2530412	AA	20050428	CA 2004-2530412	20040625
WO 2005038012	A2	20050428	WO 2004-US20958	20040625
WO 2005038012	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1641914	A2	20060405	EP 2004-777231	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
EP 1649013	A2	20060426	EP 2004-809466	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:	US 2003-483264P	P	20030627
	WO 2004-US20816	W	20040625
	WO 2004-US20958	W	20040625

AB Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

L12 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:326146 CAPLUS
DOCUMENT NUMBER: 140:344964
TITLE: Biocompatible scaffolds with tissue fragments
INVENTOR(S): Binette, Francois; Hwang, Julia; **Dhanaraj, Sridevi; Gosiewska, Anna**
PATENT ASSIGNEE(S): Ethicon, Inc., USA
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1410811	A1	20040421	EP 2003-256522	20031016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004078090	A1	20040422	US 2003-374772	20030225
AU 2003252886	A1	20040506	AU 2003-252886	20031009
CA 2445558	AA	20040418	CA 2003-2445558	20031017
JP 2004136096	A2	20040513	JP 2003-358118	20031017
AU 2006200194	A1	20060202	AU 2006-200194	20060117

PRIORITY APPLN. INFO.:	US 2002-419539P	P	20021018
	US 2002-420093P	P	20021018
	US 2003-374772	A	20030225
	AU 2003-252886	A3	20031009

AB A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biol. component that assists in healing or tissue repair. The biocompatible tissue repair implants include a biocompatible scaffold and particles of living tissue, such that the tissue and the scaffold become associated The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold. Healthy cartilage tissue from articulating joints was obtained from bovine shoulders. The cartilage tissue, which was substantially free of bone tissue, was minced using scalpel blades to obtain small tissue fragments in the presence of 0.2% collagenase. The minced tissue was then distributed uniformly on a synthetic bioresorbable polycaprolactone/polyglycolic acid scaffold. Cells migrate extensively

into the polymer scaffolds from the minced cartilage tissue fragments. The migrating cells retain their phenotype and produce matrix that stained pos. for the sulfated glycosaminoglycans by using the Safranin O stain.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5722 CAPLUS
DOCUMENT NUMBER: 138:61346
TITLE: Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints
INVENTOR(S): Thompson, Jonathan; **Gosiewska, Anna**; Niemiec, Susan; **Dhanaraj, Sridevi**
PATENT ASSIGNEE(S): Depuy, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000191	A2	20030103	WO 2002-US19718	20020620
WO 2003000191	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451248	AA	20030103	CA 2002-2451248	20020620
EP 1423081	A2	20040602	EP 2002-739947	20020620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005521629	T2	20050721	JP 2003-506637	20020620
PRIORITY APPLN. INFO.:			US 2001-300734P P	20010625
			WO 2002-US19718 W	20020620

AB A preferred embodiment of the present invention is directed to a composition and method for treating arthritis comprising one or more glycosaminoglycans in combination with one or more hyaluronidase inhibitor. In a more preferred embodiment the present invention is directed to a composition and method for treating arthritis comprising one or more glycosaminoglycans which would include at least hyaluronic acid in combination with one or more hyaluronidase inhibitors selected from the group consisting of heparan sulfate, dextran sulfate and xylose sulfate. In still a more preferred embodiment the present invention relates to a composition and method for treating arthritis comprising hyaluronic acid co-encapsulated with a hyaluronidase inhibitor in liposomes. Hyaluronic acid in the composition would confer the viscosupplement properties to the joint. The function of the hyaluronidase inhibitor would be to act as a preservative, and protect the hyaluronic acid from premature degradation in the joint. The liposomal encapsulation and delivery of the composition would serve as a slow release depot for the hyaluronic acid and the

hyaluronidase inhibitor. This invention therefore provides a means of delivering stable and long lasting high mol. weight HA to the joint. The therapeutic effectiveness of the liposome co-encapsulated hyaluronic acid with the hyaluronidase inhibitor would be greater than simple injection of hyaluronic acid. The preferred method of treatment would be by intra-articular injection of an admixt. of hyaluronic acid and a hyaluronidase inhibitor, optionally encapsulated in liposomes. The treatment is more effective than currently available treatments based on HA alone.

L12 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:794142 CAPLUS
DOCUMENT NUMBER: 137:300015
TITLE: Polymer device and method for tissue engineering
INVENTOR(S): **Yi, Chin-Feng**; **Gosiewska, Anna**; Roweton, Susan
PATENT ASSIGNEE(S): Ethicon Endo-Surgery, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002150604	A1	20021017	US 2001-832700	20010411
US 6656488	B2	20031202		
PRIORITY APPLN. INFO.:			US 2001-832700	20010411

AB A device and method for tissue engineering is disclosed. More particularly this invention relates to a bioabsorbable device and a method of its use which promotes controlled new tissue in-growth into voids or cavities occupied by the device as portions of the device are selectively absorbed within a host thereby minimizing collapse of surrounding, pre-existing host tissue into the engineered site. A membrane construction for bioabsorbable bag is composed of caprolactone-glycolide copolymer.

L12 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:716111 CAPLUS
DOCUMENT NUMBER: 137:242470
TITLE: Modulation of smooth muscle cell proliferation using VEGF-X polypeptides, nucleic acids, antibodies, and antisense nucleotides for disease treatment
INVENTOR(S): Geesin, Jeffrey C.; **Gosiewska, Anna**; Xu, Jean; Gordon, Robert; Yon, Jeff; **Dhanaraj, Sridevi Naidu**; Harris, Ian
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072127	A2	20020919	WO 2002-EP2616	20020307
WO 2002072127	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2439612	AA	20020919	CA 2002-2439612		20020307
EP 1377310	A2	20040107	EP 2002-727388		20020307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004527506	T2	20040909	JP 2002-571086		20020307
CN 1568194	A	20050119	CN 2002-806185		20020307
NZ 527975	A	20050225	NZ 2002-527975		20020307
US 2004142886	A1	20040722	US 2003-471221		20030905
NO 2003003961	A	20031105	NO 2003-3961		20030908
PRIORITY APPLN. INFO.:			US 2001-274901P	P	20010309
			WO 2002-EP2616	W	20020307

AB There is provided a novel use for vascular endothelial growth factor, herein designated VEGF-X, and a CUB domain present in the sequence of VEGF-X, which enhance smooth muscle cell proliferation and can be used to treat diseases associated with reduced smooth muscle cell proliferation. VEGF-X, and a CUB domain can also be used in tissue engineering applications to increase the number of smooth muscle cells within specific tissue to restore that tissue function or architecture. Screening methods for identifying inhibitors of VEGF-X biol. activity are also disclosed and these inhibitors include neutralizing VEGF-X antibodies, antisense VEGF-X sequences or non-protein antagonists competing with VEGF-X biol. activity. Also provided are therapeutic methods for treating disorders associated with smooth muscle cells hyperproliferation and methods of diagnosis a pathol. condition or susceptibility to a pathol. condition associated with smooth muscle cell hyperproliferation.

L12 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:134962 CAPLUS
DOCUMENT NUMBER:	137:57682
TITLE:	Characterization of platelet-derived growth factor-C (PDGF-C): expression in normal and tumor cells, biological activity and chromosomal localization
AUTHOR(S):	Dijkmans, Joyce; Xu, Jean; Masure, Stefan; **Dhanaraj, Sridevi; Gosiewska, Anna**; Geesin, Jeff; Sprengel, Jorg; Harris, Sarah; Verhasselt, Peter; Gordon, Robert; Yon, Jeff
CORPORATE SOURCE:	Department of Biotechnology & High Throughput Screening, Janssen Research Foundation, Beerse, Belg.
SOURCE:	International Journal of Biochemistry & Cell Biology (2002), 34(4), 414-426 CODEN: IJBBFU; ISSN: 1357-2725
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The predicted platelet-derived growth factor-C (PDGF-C) polypeptide contains an N-terminal CUB-like domain and a C-terminal domain with homol. to members of the PDGF/vascular endothelial growth factor (VEGF) family. PDGF-C mRNA is widely expressed in normal tissues and does not appear to be up-regulated in the tumor cell lines tested. The PDGF-C gene was

mapped to human chromosome 4q31-32. PDGF-C protein and the CUB domain of PDGF-C expressed in Escherichia coli, were able to stimulate proliferation of human artery smooth muscle cells, but were inactive on umbilical vein endothelial cells, osteoblasts, fibroblasts, skeletal muscle cells (SkMC), bovine chondrocytes, and rat myocardium cells. Although the mitogenic activity of PDGF-C and the CUB domain was only observed at concns. ranging from 1 to 10 μg/mL, substitution of Cys124 by Ser or deletion of Cys124 significantly reduced the mitogenic activity. The authors' data suggest a possible role of the CUB domain of PDGF-C in addition to its role in maintaining latency of the PDGF domain.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:563722 CAPLUS
DOCUMENT NUMBER: 136:299567
TITLE: Development of a three-dimensional transmigration assay for testing cell-polymer interactions for tissue engineering applications
AUTHOR(S): **Gosiewska, Anna**; Rezania, Alireza; **Dhanaraj, Sridevi**; Vyakarnam, Murty; Zhou, Jeff; Burtis, Diann; Brown, Laura; Kong, Wei; Zimmerman, Mark; Geesin, Jeffrey C.
CORPORATE SOURCE: Johnson & Johnson Wound Healing Technology Resource Center, Skillman, NJ, USA
SOURCE: Tissue Engineering (2001), 7(3), 267-277
CODEN: TIENFP; ISSN: 1076-3279
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ability of synthetic or natural scaffolds to support invasion of cells from surrounding tissue is a key parameter for tissue engineering (TE). In this study, the migration of fibroblasts, chondrocytes, and osteoblasts into biodegradable polymer scaffolds was evaluated using a novel, three-dimensional (3-D) transmigration assay. This assay is based on a cell-populated contracted collagen lattice with a biodegradable polymer scaffold implanted at the center of the collagen gel. Cell migration into the scaffolds was assessed both quant. and qual. following various time lengths in culture using image anal. Chondrocytes, incorporated within the collagen lattice, migrated into polymer scaffolds, when cultured both statically or in a rotating bioreactor. However, the bioreactor cultures resulted in a significantly greater cell invasion as compared to static cultures. There was a cell d.-dependent osteoblast migration from collagen lattice into polymer scaffold, when tested in the transmigration assay. In addition, polymer scaffolds, treated with or without recombinant human platelet-derived growth factor (rh-PDGF-BB) were evaluated for fibroblast migration. The presence of rh-PDGF-BB resulted in significantly greater fibroblast invasion as compared to untreated scaffolds. Our studies suggest that the transmigration model provides a rapid system for testing cell invasion of potential scaffolds for tissue engineering applications.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:207754 CAPLUS
DOCUMENT NUMBER: 135:42565
TITLE: Incorporation of Fluorescent Enzyme Substrates in Agarose Gel for in Situ Zymography

AUTHOR(S): **Yi, Chin-Feng; Gosiewska, Anna;** Burtis, Diann; Geesin, Jeffrey
CORPORATE SOURCE: Johnson & Johnson, Wound Healing Technology Resource Center, Skillman, NJ, 08558, USA
SOURCE: Analytical Biochemistry (2001), 291(1), 27-33
CODEN: ANBCA2; ISSN: 0003-2697
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The currently available methods for the detection of proteases in tissue sections are characterized by limited substrate specificity and low sensitivity and are also cumbersome. We have developed a novel in situ zymog. method that uses a synthetic substrate conjugated to a fluorescent tag for detection of proteases in tissue sections. In the presence of active enzyme, the fluorescent tag is cleaved off from the substrate peptide chain resulting in an approx. 100-fold increase in the fluorescent signal. In order to minimize the diffusion of the fluorescent tag, the substrate is incorporated into 1% agarose prior to overlaying onto the tissue section. This method retains the morphol. details of the tissue section, is highly sensitive and specific for the designated peptide sequence, and provides information regarding the functional status of the enzyme. Thus, this method could be used for detection and monitoring of enzymic activity in tissue sections for a variety of applications. (c) 2001 Academic Press.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:441935 CAPLUS
DOCUMENT NUMBER: 133:85148
TITLE: Cloning and characterization of vascular endothelial growth factor-x (VEGF-X) gene and its therapeutic application in angiogenesis or vascularization related disorders
INVENTOR(S): Gordon, Robert Douglas; Sprengel, Jorg Jurgen; Yon, Jeffrey Roland; Dijkmans, Josiena Johanna Huberdina; **Gosiewska, Anna; Dhanaraj, Sridevi Naidu;** Xu, Jean
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037641	A2	20000629	WO 1999-US30503	19991221
WO 2000037641	A3	20001019		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2356009	AA	20000629	CA 1999-2356009		19991221
EP 1141293	A2	20011010	EP 1999-968929		19991221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
NZ 512892	A	20030829	NZ 1999-512892		19991221
US 6783953	B1	20040831	US 1999-468647		19991221
AU 778412	B2	20041202	AU 2000-27124		19991221
US 2005153882	A1	20050714	US 2004-924025		20040823
PRIORITY APPLN. INFO.:			GB 1998-28377	A	19981222
			US 1999-124967P	P	19990318
			US 1999-164131P	P	19991108
			US 1999-468647	A3	19991221
			WO 1999-US30503	W	19991221

AB A novel vascular endothelial growth factor, VEGF-X, is identified by searching the public databases and Incyte LifeSeq database for two conserved protein domains: VEGF-like domain and CUB domain of known VEGF proteins. The full-length cDNA of VEGF-X is cloned by PCR and 5'-RACE, and used to express full-length protein or its fragments containing VEGF domain or CUB domain in mammalian cell lines or Escherichia coli. The studies of tissue distribution of VEGF-X mRNA, of disulfide-linked dimerization or glycosylation of VEGF-X protein, of the effect on full-length or truncated (CUB domain-containing) VEGF-X on HuVEC cell profileration, and of cytotoxicity of CUB domain peptides are presented. Methods of using VEGF-X cDNA or protein sequence to treat diseases associated with inappropriate vascularization or angiogenesis and screen for drugs to inhibit or enhance angiogenesis, and preparation antibody for therapeutic and diagnostic use are provided.

```
=> d que l4
L1             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L3           9 SEA FILE=REGISTRY SSS FUL L1
L4          13 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3


=> d ibib abs hitstr l4 tot

L4   ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:75322  CAPLUS
DOCUMENT NUMBER:         144:177371
TITLE:                   Therapeutic peptides, conjugated to antibody Fc and
                         water-soluble polymer, with improved bioefficacy in
                         multidose administration
INVENTOR(S):             Walker, Kenneth William; Kinstler, Olaf B.; Stiney,
                         Karen
PATENT ASSIGNEE(S):      Amgen Inc., USA
SOURCE:                  PCT Int. Appl., 119 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
    ---------------      ----   --------    --------------------   --------
```

WO 2006010057 A2 20060126 WO 2005-US24373 20050708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-586419P P 20040708

AB The invention relates to compds. that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers. Thus, a murine Fc domain fused to a c-Mpl-binding peptide, a thrombopoietin mimic, was prepared with transgenic E. coli. The recombinant protein was modified by reaction with methoxypolyethylene glycol aldehyde. This PEGylated protein was shown to induce platelet aggregation that did not decrease when administered to mice in a multiple dosage regimen.

IT **268228-13-3**
RL: PRP (Properties)
(unclaimed protein sequence; therapeutic peptides, conjugated to antibody Fc and water-soluble polymer, with improved bioefficacy in multidose administration)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1333961 CAPLUS
DOCUMENT NUMBER: 144:64389
TITLE: α-MSH-, γ-MSH-, and bombesin-derived metallopeptide compounds
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Rajpurohit, Ramesh; Cai, Hui-Zhi; Bastos, Margarita
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 769,695.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005282739	A1	20051222	US 2005-188552	20050725
WO 2002064734	A2	20020822	WO 2001-US50075	20011219
WO 2002064734	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005014193	A1	20050120	US 2003-464117	20030617
US 2004248212	A1	20041209	US 2004-769695	20040130

PRIORITY APPLN. INFO.:		
US 2000-256842P	P	20001219
US 2001-304835P	P	20010711
US 2001-327835P	P	20011004
WO 2001-US50075	A2	20011219
US 2003-444129P	P	20030131
US 2003-464117	A2	20030617
US 2004-769695	A2	20040130
US 2004-590933P	P	20040723

AB The invention discloses metallopeptides with a sequence of a biol. active α-MSH, γ-MSH, or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline residue which is either of the two residues on the immediately adjacent amino-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog. In one embodiment, the metal atom is rhenium.

IT **754240-92-1D**, metal complexes **871542-49-3D**, metal complexes
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(α-MSH-, γ-MSH-, and bombesin-derived metallopeptide

compds.)

RN 754240-92-1 CAPLUS

CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

—OH

RN 871542-49-3 CAPLUS
CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:323999 CAPLUS
DOCUMENT NUMBER: 142:386021
TITLE: Peptide with osteogenic activity, and therapeutic use
INVENTOR(S): Dhanaraj, Sridevi; Gosiewska, Anna; Rezania, Ali; Heavner, George A.; Lin, Xuanhan; Yi, Chin-Feng
PATENT ASSIGNEE(S): Ethicon, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032461	A2	20050414	WO 2004-US29649	20040910

WO 2005032461 A3 20050707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005187162 A1 20050825 US 2003-674516 20030930
PRIORITY APPLN. INFO.: US 2003-674516 A 20030930
OTHER SOURCE(S): MARPAT 142:386021

AB The invention provides a composition including an isolated or recombinant peptide component that has osteogenic cell proliferative activity. The peptide, which promotes proliferation of osteoblasts, is useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis and periodontic diseases, and for prevention of fractures associated with osteoporosis and rheumatoid arthritis. The peptide, or cells that have been genetically engineered to produce the peptide, can be combined with a bone-compatible matrix to facilitate slow release of the peptide to a treatment site and/or provide a structure for developing bone.

IT **849774-60-3**
RL: DEV (Device component use); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptide with osteogenic activity, and therapeutic use)

RN 849774-60-3 CAPLUS
CN Glycine, L-cysteinylglycylglycylglycyl-L-arginyl-L-tryptophyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



$-CO_2H$

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1060669 CAPLUS
DOCUMENT NUMBER: 142:34829
TITLE: Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Bastos, Margarita; Rajpurohit, Ramesh; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 464,117.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248212	A1	20041209	US 2004-769695	20040130
WO 2002064734	A2	20020822	WO 2001-US50075	20011219
WO 2002064734	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005014193	A1	20050120	US 2003-464117	20030617
CA 2516750	AA	20040910	CA 2004-2516750	20040202
WO 2004075830	A2	20040910	WO 2004-US2933	20040202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1594442 A2 20051116 EP 2004-737267 20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2005282739 A1 20051222 US 2005-188552 20050725
PRIORITY APPLN. INFO.: US 2000-256842P P 20001219
US 2001-304835P P 20010711
US 2001-327835P P 20011004
WO 2001-US50075 A1 20011219
US 2003-444129P P 20030131
US 2003-464117 A2 20030617
US 2004-769695 A 20040130
WO 2004-US2933 W 20040202
US 2004-590933P P 20040723

AB The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of a peptide or protein. A residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of the peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide with a conformationally fixed and predictable secondary structure of the residues involved in metal ion complexation. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality. The method is exemplified by α-MSH and bombesin analogs containing L-/D-cysteine insertions or substitutions complexed to the rhenium metal ion, and their binding to their resp. receptors.

IT **754240-34-1D**, complex with rhenium metal ion **754240-92-1D**
, complex with rhenium metal ion
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs)

RN 754240-34-1 CAPLUS

CN L-Valine, L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

—OH

RN 754240-92-1 CAPLUS
CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740117 CAPLUS
DOCUMENT NUMBER: 141:256945
TITLE: Knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs
INVENTOR(S): Sharma, Shubh D.; Shi, Yi-Qun; Rajpurohit, Ramesh; Bastos, Margarita; Cai, Hui-Zhi
PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075830	A2	20040910	WO 2004-US2933	20040202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248212	A1	20041209	US 2004-769695	20040130
CA 2516750	AA	20040910	CA 2004-2516750	20040202
EP 1594442	A2	20051116	EP 2004-737267	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:		
US 2003-444129P	P	20030131
US 2004-769695	A	20040130
US 2000-256842P	P	20001219
US 2001-304835P	P	20010711
US 2001-327835P	P	20011004
WO 2001-US50075	A1	20011219
US 2003-464117	A2	20030617
WO 2004-US2933	W	20040202

AB The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. A residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of the peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide with a conformationally fixed and predictable secondary structure of the residues involved in metal ion complexation. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality. The method is exemplified by α-MSH and bombesin analogs containing L-/D-cysteine insertions or substitutions complexed to the rhenium metal ion, and their binding to their resp. receptors.

IT **754240-34-1D**, complex with rhenium metal ion **754240-92-1D**
, complex with rhenium metal ion
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(knockout identification of target-specific sites in peptides by serial substitution of conformationally restricted metal-complexed residues in metallopeptide analogs)

RN 754240-34-1 CAPLUS

CN L-Valine, L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

—OH

RN 754240-92-1 CAPLUS
CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-D-cysteinylglycyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:20444 CAPLUS
DOCUMENT NUMBER: 140:110119
TITLE: Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002424	A2	20040108	WO 2003-US20495	20030630
WO 2004002424	C1	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490411	AA	20040108	CA 2003-2490411	20030630
AU 2003256336	A1	20040119	AU 2003-256336	20030630
BR 2003012276	A	20050426	BR 2003-12276	20030630
US 2005191301	A1	20050901	US 2003-609783	20030630
EP 1575499	A2	20050921	EP 2003-762210	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536992	T2	20051208	JP 2004-518080	20030630
CN 1735433	A	20060215	CN 2003-820110	20030630
PRIORITY APPLN. INFO.:			US 2002-392431P P	20020628
			US 2002-412144P P	20020919
			WO 2003-US20495 W	20030630

AB The present invention relates to at least one novel erythropoietin (EPO) human CH1-deleted mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one CH1-deleted mimetibody or specified portion or variant, CH1-deleted mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compns., methods and devices. Peptides that mimic the activity of EPO, TPO, growth hormones, G-CSF, GM-CSF, IL-1, leptin, CTLA4, TRAIL, TGF-α, and TGF-β are the focus of this genetic engineering. The CH1 deleted mimetibody can optionally comprise at least one CH3 constant region directly linked with at least one CH2 region directly linked with at least one hinge region or fragment thereof directly linked with at least one partial V region, directly linked with an optional linker sequence, directly linked to at least one therapeutic peptide, optionally further directly linked with at least a portion of at least one variable antibody sequence. In a preferred embodiment a pair of a CH3-CH2-hinge-partial J sequence-linker-therapeutic peptide with an option N-terminal antibody sequence, the pair optionally linked by association or covalent linkage, such as, but not limited to, a Cys-Cys disulfide bond. The aim of the invention is use of the purified recombinant proteins for diagnosis or treatment of anemia, immune or autoimmune disease, cancer, or infectious diseases.

IT **268228-13-3**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, mimetibody comprising; mammalian EPO mimetic CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:20438 CAPLUS
DOCUMENT NUMBER: 140:110118
TITLE: Mammalian CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002417	A2	20040108	WO 2003-US20347	20030627
WO 2004002417	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490409	AA	20040108	CA 2003-2490409	20030627
AU 2003280130	A1	20040119	AU 2003-280130	20030627
EP 1545608	A2	20050629	EP 2003-742272	20030627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504406	T2	20060209	JP 2004-517981	20030627
PRIORITY APPLN. INFO.:			US 2002-392431P P	20020628
			WO 2003-US20347 W	20030627

AB The present invention relates to at least one novel human CH1-deleted mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one CH1-deleted mimetibody or specified portion or variant, CH1-deleted mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compns., methods and devices. In one embodiment, a CH1 deleted mimetibody comprises formula: (V1(n)-Pep(n)-Flex(n)-V2(n)-pHinge(n)-CH2(n)-CH3(n))(m), where V1 is at least one portion of an N-terminus of an Ig variable region, Pep is at least one bioactive peptide, Flex is polypeptide that provides structural flexibility by allowing the mimetibody to have alternative orientations and binding properties, V2 is at least one portion of a C-terminus of an Ig variable region, pHinge is at least a portion of an Ig variable hinge region, CH2 is at least a portion of an Ig CH2 constant region, CH3 is at

least a portion of an Ig CH3 constant region, n and m can be an integer between 1 and 10. Peptides that mimic the activity of EPO, TPO, growth hormones, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF-α and TGF-β are the focus of this genetic engineering. The aim of the invention is use of the purified recombinant proteins for diagnosis or treatment of anemia, immune or autoimmune disease, cancer, or infectious diseases.

IT **268228-13-3**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, mimetibody comprising; mammalian CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:830375 CAPLUS
DOCUMENT NUMBER: 139:303032
TITLE: Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human tissues
INVENTOR(S): Penn, Sharron Gaynor; Rank, David Russell; Hanzel, David Kagen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 80 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003194704	A1	20031016	US 2002-29386		20020403
US 2003194704	A1	20031016	US 2002-29386		20020403
PRIORITY APPLN. INFO.:			US 2002-29386	A	20020403

AB Methods and apparatus for predicting, confirming and displaying functional regions from genomic sequence data are used to identify unique human genome-derived single exon probes useful for gene expression anal., particularly gene expression anal. by microarray. Human BAC sequences totaling .apprx.350 Mb of sequence (.apprx.10% of the human genome) were

analyzed for exons using four sep. gene finding programs (GRAIL uses a neural network, GENEFINDER uses a hidden Markoff model, DICTION operates according to a different heuristic, and GENSCAN) and Mouse comparative genomics as a fifth gene prediction method. The exons were PCR amplified from genomic DNA, verified on agarose gels, and sequenced using universal primers to validate the identity of the amplicon to be spotted in microarrays. Thus, expression, homol., and functional information are provided for 13,700 unique genome-derived single exon probes are expressed at significant levels in one or more of 8 tested tissues: human brain, heart, fetal and adult liver, placenta, lung, bone marrow, and HeLa cells. The probes lack prokaryotic and bacteriophage vector sequences, as well as lacking homopolymeric stretches of A or T. Also presented are genome-derived single exon microarrays that include such probes, peptides encoded by the exons, and antibodies thereto. In addition, methods are provided for identifying exons in a eukaryotic genome, and for assigning exons to a single gene. [This abstract record is one of nine records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **610771-20-5 610774-96-4**
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human genome-derived single exon nucleic acid probes useful for anal. of gene expression in human tissues)

RN 610771-20-5 CAPLUS

CN L-Alanine, L-leucyl-L-arginylglycyl-L-prolyl-L-glutaminyl-L-seryl-L-prolyl-L-arginyl-L-cysteinyl-L-lysyl-L-prolyl-L-valyl-L-leucyl-L-valyl-L-histidylglycyl-L-glutaminyl-L-leucylglycyl-L-threonyl-L-arginyl-L-prolyl-L-cysteinyl-L-seryl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-A







L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818235 CAPLUS
DOCUMENT NUMBER: 139:322283
TITLE: Methods for production and use of mammalian complementarity determining region mimetibodies for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Scallon, Bernard J.; Ghrayeb, John
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084477	A2	20031016	WO 2003-US9139	20030324
WO 2003084477	A3	20050909		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003222069	A1	20031020	AU 2003-222069	20030324
EP 1572079	A2	20050914	EP 2003-718053	20030324
EP 1572079	A3	20051102		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-368791P	P 20020329
	WO 2003-US9139	W 20030324

AB This invention pertains to methods for production and use of mammalian complementarity determining region (CDR) mimetibodies for diagnosis and therapy of human diseases. Genetic engineering, expression, and purification of human mimetibodies containing Ig fragments (CDR, variable, framework and/or constant region) as well as a ligand binding domain are disclosed in this invention. Peptides that mimic the activity of EPO, TPO, growth hormones, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF-α and TGF-β are the focus of this genetic engineering. The aim of the invention is use of the purified recombinant proteins for diagnosis or treatment of anemia, immune or autoimmune disease, cancer, or infectious diseases. At the time of publication, claimed sequence nos. 997 to 1109 were missing, and claimed sequence nos. 984 to 996 were not clearly identified.

IT **268228-13-3**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calmodulin antagonist peptide; methods for production and use of mammalian CDR mimetibodies for diagnosis and therapy of human diseases)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:888494 CAPLUS
DOCUMENT NUMBER: 137:381503
TITLE: Compositions and methods for modulating Dkk-mediated protein interactions and their diagnostic and therapeutic uses
INVENTOR(S): Allen, Kristina; Anisowicz, Anthony; Bhat, Bheem M.; Damagnez, Veronique; Robinson, John Allen; Yaworsky, Paul J.
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA; Wyeth, John and Brother Ltd.
SOURCE: PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092015	A2	20021121	WO 2002-US15982	20020517
WO 2002092015	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446582	AA	20021121	CA 2002-2446582	20020517
EP 1395285	A2	20040310	EP 2002-744162	20020517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009836	A	20041207	BR 2002-9836	20020517
JP 2005512508	T2	20050512	JP 2002-588934	20020517
US 2004038860	A1	20040226	US 2002-182936	20020802

PRIORITY APPLN. INFO.:

US 2001-291311P	P	20010517
US 2002-353058P	P	20020201
US 2002-361293P	P	20020304
WO 2002-US15982	W	20020517

AB The present invention provides reagents, compds., compns., and methods relating to interactions of the extracellular domain of LRP5/ZMax1, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. The invention claims sequences for peptide aptamers which bind to LRP5 or Dkk-1 and sequences for Dkk-1 peptides which are recognized by antibodies. HBM is a Gly171Val polymorphism in LDL receptor-related protein LRP5/Zmax, which has been identified as conferring a high bone mass phenotype in a population of related humans. The protein dickkopf-1 (Dkk-1) is required for head formation in early development and murine limb morphogenesis and is reported to be an antagonist of the Wnt signaling pathway. Dkk-1 protein interacts with the ligand-binding domain of LRP5. Dkk-1 also binds to LRP6, but the EGF repeat domains of LRP6 rather than the

ligand-binding domain are required for interaction. Dkk-1 is able to repress LRP5-mediated Wnt signaling but not HBM-mediated Wnt signaling and Dkk-1 also inhibits LRP6 activity. LRP5, LRP6, HBM, Dkk and Wnt are implicated in bone and lipid cellular signaling. Thus, the present invention provides reagents and methods for modulating lipid levels and/or bone mass and is useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis. Examples of the invention include a yeast two-hybrid screen for Dkk-1 interacting proteins, generation of LRP5 polymorphism-specific antibodies and Dkk-1 specific antibodies, effects of exogenous Dkk-1 on Wnt-mediated signaling in the Xenopus embryo assay, and effects of recombinant Dkk and Wnt3a/1 on TCF-luciferase reporter gene expression in human cell lines with endogenous LRP5/6.

IT **476153-38-5**

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(LRP5 ligand-binding domain-interacting peptide aptamer; compns. and methods for modulating Dkk-mediated protein interactions and their diagnostic and therapeutic uses)

RN 476153-38-5 CAPLUS

CN L-Valine, glycyl-L-tryptophyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl-L-arginyl-L-cysteinylglycyl-L-alanyl-L-leucyl-L-tryptophyl-L-tryptophyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:816705 CAPLUS
DOCUMENT NUMBER: 135:366701
TITLE: Fc-domain-modified peptides as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-Fa; Cheetham, Janet C.; Boone, Thomas Charles; Gudas, Jean Marie
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083525	A2	20011108	WO 2001-US14310	20010502

WO 2001083525 A3 20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2407956	AA	20011108	CA 2001-2407956 20010502
EP 1278778	A2	20030129	EP 2001-932951 20010502
JP 2003533187	T2	20031111	JP 2001-580949 20010502
US 2005123548	A1	20050609	US 2003-645784 20030818
US 2004077022	A1	20040422	US 2003-666696 20030919

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2000-563286	A	20000503
US 1998-105371P	P	19981023
US 1999-428082	A2	19991022
WO 2001-US14310	W	20010502

AB The present invention concerns fusion of Fc domains with biol. active peptides and a process for preparing pharmaceutical agents using biol. active peptides. In this invention, pharmacol. active compds. are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacol. agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E.coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural anal.

IT **268228-13-3**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fc-domain-modified peptides as therapeutic agents)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:780431 CAPLUS
DOCUMENT NUMBER: 134:68132
TITLE: Melanoma-targeting properties of 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues
AUTHOR(S): Chen, JianQing; Cheng, Zhen; Hoffman, Timothy J.; Jurisson, Silvia S.; Quinn, Thomas P.
CORPORATE SOURCE: Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, 65211, USA
SOURCE: Cancer Research (2000), 60(20), 5649-5658
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Preliminary reports have demonstrated that 99mtechnetium (Tc)-labeled cyclic [Cys3,4,10, D-Phe7]α-MSH3-13 (CCMSH) exhibits high tumor uptake and retention values in a murine melanoma mouse model. In this report, the tumor targeting mechanism of 99mTc-CCMSH was studied and compared with four other radiolabeled α-MSH (α-MSH) peptide analogs: 125I-(Tyr2)-[Nle4, D-Phe7]α-MSH [125I-(Tyr2)-NDP]; 99mTc-CGCG-NDP; 99mTc-Gly11-CCMSH; and 99mTc-Nle11-CCMSH. In vitro receptor binding, internalization, and cellular retention of radiolabeled α-MSH analogs in B16/F1 murine cell line demonstrated that >70% of the receptor-bound radiolabeled analogs were internalized together with the receptor. Ninety % of the internalized 125I-(Tyr2)-NDP, whereas only 36% of internalized 99mTc-CCMSH, was released from the cells into the medium during a 4-h incubation at 37°C. Two mouse models, C57 mice and severe combined immunodeficient (Scid) mice, inoculated s.c. with B16/F1 murine and TXM-13 human melanoma cells were used for the in vivo studies. Tumor uptake values of 11.32 and 2.39 [% injected dose (ID)/g] for 99mTc-CCMSH at 4 h after injection, resulted in an uptake ratio of tumor:blood of 39.0 and 11.5 in murine melanoma-C57 and human melanoma-Scid mouse models, resp. Two strategies for decreasing the nonspecific kidney uptake of 99mTc-CCMSH, substitution of Lys11 in CCMSH with Gly11 or Nle11, and lysine coinjection, were evaluated. The biodistribution data for the modified peptides showed that Lys11 replacement dramatically decreased the kidney uptake, whereas the tumor uptakes of 99mTc-Nle11- and 99mTc-Gly11-CCMSH were significantly lower than that of 99mTc-CCMSH. Lysine coinjection significantly decreased the kidney uptake (e.g., from 14.6% ID/g to 4.5% ID/g at 4 h after injection in murine melanoma-C57 mice) without significantly changing the value of tumor uptake of 99mTc-CCMSH. In conclusion, the compact cyclic structure of 99mTc-CCMSH, its resistance to degradation, and its enhanced intracellular retention are the major contributing factors to the superior in vivo tumor targeting properties of 99mTc-CCMSH. Lys11 residue in 99mTc-CCMSH is critical to the tumor targeting in vivo, and lysine coinjection rather than lysine replacement can significantly decrease the nonspecific renal radioactivity accumulation without impeding the high melanoma-targeting properties of 99mTc-CCMSH. The metal-cyclized CCMSH mol. displays excellent potential for the development of melanoma-specific diagnostic and therapeutic agents.

IT **315377-55-0D**, 99mTc complex
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(melanoma-targeting properties of 99mTc-labeled α-MSH peptide analogs)
RN 315377-55-0 CAPLUS

CN L-Valinamide, N-acetyl-L-cysteinyl-L-cysteinyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl-L-prolyl- (9CI). (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:291095 CAPLUS
DOCUMENT NUMBER: 132:329919
TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025
WO 2000024782	A3	20020606		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6660843	B1	20031209	US 1999-428082	19991022
CA 2347131	AA	20000504	CA 1999-2347131	19991025
EP 1144454	A2	20011017	EP 1999-971003	19991025
EP 1144454	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914708	A	20020716	BR 1999-14708	19991025
JP 2003512011	T2	20030402	JP 2000-578351	19991025
AU 767725	B2	20031120	AU 2000-12322	19991025
NZ 510888	A	20040130	NZ 1999-510888	19991025
NZ 528882	A	20050624	NZ 1999-528882	19991025
CN 1721447	A	20060118	CN 2005-10082591	19991025
CN 1746189	A	20060315	CN 2005-10083696	19991025
CN 1746190	A	20060315	CN 2005-10083697	19991025
ZA 2001002753	A	20020611	ZA 2001-2753	20010404
NO 2001001963	A	20010621	NO 2001-1963	20010420
BG 105461	A	20030430	BG 2001-105461	20010424
US 2004044188	A1	20040304	US 2003-609217	20030627
US 2004053845	A1	20040318	US 2003-632388	20030731
US 2004071712	A1	20040415	US 2003-645761	20030818
US 2005123548	A1	20050609	US 2003-645784	20030818
US 2004057953	A1	20040325	US 2003-651723	20030829
US 2004087778	A1	20040506	US 2003-653048	20030829
US 2004077022	A1	20040422	US 2003-666696	20030919
AU 2004200687	A1	20040318	AU 2004-200687	20040220
AU 2004200690	A1	20040318	AU 2004-200690	20040220
AU 2004200691	A1	20040318	AU 2004-200691	20040220
PRIORITY APPLN. INFO.:			US 1998-105371P P	19981023
			US 1999-428082 A	19991022

AU 2000-12322	A3	19991025
CN 1999-814727	A3	19991025
WO 1999-US25044	W	19991025
US 2000-563286	A1	20000503
AU 2004-200687	A	20040220

AB The present invention concerns fusion of Fc domains with biol. active peptides and a process for preparing pharmaceutical agents using biol. active peptides. In this invention, pharmacol. active compds. are prepared by a process comprising: (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacol. agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, Escherichia coli coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.

IT **268228-13-3D**, fusion protein with IgG1 Fc domain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calmodulin antagonist; modified peptides containing an antibody Fc domain as therapeutic agents)

RN 268228-13-3 CAPLUS

CN L-Serine, L-seryl-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-tryptophylglycyl-L-lysyl-L-leucyl-L-arginyl-L-tryptophyl-L-cysteinylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A